|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Bridging the Gap in Microhematuria Evaluation: A Discussion on the STRATA Trial |
| Yair Lotan, MD |
| Yair Lotan discusses the STRATA trial, a multicenter study comparing the Cxbladder Triage test to traditional cystoscopy in patients with microhematuria. This trial explores whether a high negative predictive value biomarker test can safely reduce the number of unnecessary cystoscopies in low-risk patients. |
|
|
|
|
|
|
|
|
|
|
|
| Leveraging AI Biomarkers to Navigate the Evolving Landscape of Bladder Cancer Treatment |
Stephen Williams, MD, MS, FACS, FACHE
Zach Klaassen hosts Stephen B Williams to discuss an innovative AI biomarker for non-muscle invasive bladder cancer. Dr. Williams emphasizes the significance of refining clinical predictors for bladder cancer, highlighting the potential of the AI biomarker to revolutionize treatment approaches. |
|
|
|
|
|
|
|
|
|
|
| Exploring Tumor Biomarkers in Urothelial Carcinoma: Insights and Advancements in Bladder Cancer Research |
Chad Ritch, MD, MBA
Sam Chang is joined by Chad Ritch for a discussion on tumor biomarkers and urothelial carcinoma. They discuss various types of biomarkers, including tissue-based and liquid-based markers. |
|
|
|
|
|
|
|
|
|
|
| A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients with Microhematuria: The STRATA Trial: Safe Testing of Risk for Asymptomatic Microhematuria Trial
|
| Yair Lotan, MD
|
| Yair Lotan presented the STRATA trial results, comparing Cxbladder Triage to cystoscopy in patients with microhematuria. The study demonstrated that using Cxbladder Triage significantly reduced the number of cystoscopies by 59% in low-risk patients. Additionally, the Cxbladder test showed a high sensitivity of 90% and a negative predictive value of 99%, suggesting its efficacy as a triage tool for patients with low-risk hematuria.
|
|
|
|
|
|
| Role of Urinary Markers in Surveillance of NMIBC Patients
|
| Yair Lotan, MD, Kamal Pohar, MD, Kelly Bree, MD
|
| Kamal Pohar, Yair Lotan, and Kelly Bree discuss the role of urinary markers in the surveillance of NMIBC patients. Dr. Lotan presented a case and polled the audience, revealing that 85% do not use urinary markers besides cytology to reduce cystoscopy intervals. Dr. Bree advocated for using urinary markers to reduce the frequency of cystoscopies, while Dr. Pohar argued against their use, citing limitations in sensitivity and specificity. Dr. Lotan concluded that alternating markers with cystoscopy might be safe for intermediate-risk low-grade disease, but more evidence is needed to change current guidelines.
|
|
|
|
|
|
|
|
|
|
|
| Development and Validation of Generalizable Interpretable AI Biomarkers to Predict Clinical Outcomes in BCG-Treated Patients with Non-Muscle Invasive Bladder Cancer |
| Stephen Williams, MD, MS, FACS |
| Stephen Williams presented on developing and validating generalizable AI biomarkers to predict outcomes in BCG-treated non-muscle invasive bladder cancer patients. The study involved patients from 12 cancer centers across 4 continents, focusing on diverse patient demographics and various pathology scanners. The AI model, trained with extensive pathology data, demonstrated high accuracy in predicting recurrence and progression, outperforming traditional risk models. |
|
|
|
|
|
| No Need for TURBT, VI-RADS Makes the Diagnosis
|
| Valeria Panebianco, MD
|
| Valeria Panebianco presents on the Vesical Imaging-Reporting and Data System (VI-RADS) as a potential alternative or complement to transurethral resection of bladder tumor (TURBT) for diagnosing bladder cancer. VI-RADS uses MRI to assess the likelihood of muscle invasion, aiming to address limitations of TURBT, such as disease understaging and operator dependency.
|
|
|
|
|
|
| Predictive Biomarkers in Sarcomatoid and Rhabdoid Bladder Urothelial Carcinoma - Expert Commentary
|
| Bishoy Faltas, MD
|
| Antibody-drug conjugates have revolutionized the treatment of metastatic urothelial carcinoma. These include sacituzumab govitecan targeting TROP-2 and enfortumab vedotin targeting NECTIN-4. The conventional urothelial cancers express TROP-2 and NECTIN-4, the protein targets of these ADCs. However, little is known about the expression of these proteins in undifferentiated subtypes including sarcomatoid or rhabdoid features.
|
|
|
|
|
|
| Initial Staging in Bladder Cancer: Histologic Subtype, Molecular Phenotype, and Biomarkers Are Enough |
| Eva Comperat, MD, Ph.D. |
| Eva Comperat highlights that histologic subtypes, molecular phenotypes, and biomarkers are sufficient for the initial staging of bladder cancer, emphasizing their diagnostic, prognostic, and therapeutic significance. Molecular subtyping offers additional insights into treatment responses and metastatic patterns, supporting a more personalized approach to bladder cancer management. |
|
|
|
|
|
|
|
|
|
|
